(thirdQuint)AMPLATZER Amulet LAA Occluder Trial.

 The Amulet IDE trial is a prospective, randomized, multi-center active control worldwide trial, designed to evaluate the safety and effectiveness of the AMPLATZER cent Amulet cent Left Atrial Appendage Occluder.

 Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device (treatment) or a Boston Scientific WATCHMAN(R) LAA closure device (Control).

 The trial will be conducted at up to 150 sites worldwide.

 All enrolled subjects will follow the protocol-required tests and assessments at each scheduled follow-up visit.

.

 AMPLATZER Amulet LAA Occluder Trial@highlight

The Amulet cent device will be evaluated for safety and efficacy by demonstrating its performance is non-inferior to the commercially available WATCHMAN(R) left atrial appendage closure device in patients with non-valvular atrial fibrillation.

 Patients who are eligible for the trial will be randomized to receive either the Amulet device or the WATCHMAN device and will be followed for 5 years after device implant.

